and thrombosis are shown to be important in the pathogenesis. [1] [2] [3] Endothelial progenitor cells (EPCs) are bone marrow-derived heterogeneous immature cells which appear in neovascularization and vascular homeostasis. 4, 5 In response to vascular inflammation, injury, or tissue ischemia, they migrate to the peripheral circulation and convert into mature endothelial cells to reestablish vascular integrity and blood supply. [6] [7] [8] [9] EPCs express CD34 and EPCs from bone marrow into the peripheral blood. 11, 12 In the currently available human data, there are limited studies that have investigated the association between EPC levels and disease activity in BD, and the results of such studies are inconsistent in respect to EPC levels and the relationship to disease activity, mainly due to the different protocols used for EPC quantitation. 9, 13, 14 Also, correlation of EPCs with well-known inflammatory markers such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), VEGF, and MMP-9 levels in patients with BD have not been studied to date on a large scale.
This study aims to evaluate the levels of EPCs, CECs, VEGF, and MMP-9 in patients with Behçet's disease and to investigate their relationship to disease activity.
METHODS

Study design and groups
A total of 45 patients with BD diagnosed according to the criteria of the International Study Group for Behçet's Disease, and 28 healthy control volunteers were included in this case-control cross-sectional study. 15 The Hospital Ethics Committee approved the study, and written informed consent was obtained from all subjects. All procedures complied with Good Clinical Practice standards, the ethical standards of the Responsible Committee on Human Experimentation, and the Declaration of Helsinki.
Exclusion criteria for the control group were use of any medication, signs and symptoms of any clinical infection or systemic disease, and any invasive procedure during the month before blood collection. In the patient group, individuals with a diagnosis of any chronic illness other than BD or symptoms or history of coronary artery disease, malignancy, and pregnancy were excluded.
Patients with at least one mucocutaneous lesion or active organ involvement were considered to have "active disease" (n=32). Patients who did not have any mucocutaneous lesions or systemic complaints at the time of blood collection were defined as having "inactive disease" (n=13).
Blood sample collection and analysis
Peripheral blood samples were drawn into tubes containing ethylenediaminetetraacetic acid (EDTA) as an anticoagulant and gel tubes without anticoagulant in the morning after overnight fasting.
Samples were centrifuged immediately for 15 minutes at 3000 rpm at 4°C; then, the plasma and serum were stored at -80°C until being assayed. Blood samples with the anticoagulant were used the same day for analysis of EPCs and CECs. with BD, respectively. All of these variables were significant markers for BD. When compared to CRP and ESR as classical inflammatory markers, EPCs and CECs were found to be weaker ( Figure 3A ).
As for disease activity, all the variables except CECs showed similar marker effects ( Figure 3B ).
DISCUSSION
The main goal of this study was to define the levels of EPCs and CECs (CD34+CD133+) were significantly increased in BD in comparison with healthy controls. In addition, the number of EPCs in patients within the active period of the disease was significantly increased compared to patients with inactive disease.
Fadini et al. evaluated EPC levels in BD and associated
BD with progressive EPC decline. 9 They reported that patients with BD had significantly lower levels of EPCs (CD34+KDR+ and CD34+CD133+KDR+) than controls. However, our study showed significantly elevated levels of EPCs in patients with BD when compared to controls. This group also observed that some patients with higher disease activity had higher EPC levels, similar to our current findings, and concluded that EPC mobilization might occur during bursts of vascular inflammation. They concluded that while acute inflammation increases EPCs, over the long term a chronic inflammatory state may be accompanied by progressive EPC reduction.
This hypothesis is consistent with data on other chronic diseases.
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FIgure 1: Linear correlations between early EPCs and CRP in BD patients
FIgure 2: Linear correlations between early EPCs and CECs in BD patients
For instance, while unstable angina pectoris is characterized by increased EPC levels, chronic ischemic heart disease evolves with progressively reduced EPCs. 16, 17 On this point, they also reported that disease chronicity was the primary adverse modulator of EPC levels. This was confirmed by the multivariate analysis showing BD duration as the only independent variable associated with EPC count. However, our study did not find any association between EPCs and disease duration, which may be due to the relatively shorter disease duration in our patients.
In another study, Bozkirli et al. reported no difference in
EPCs (CD146, CD31, and CD34) levels between BD patients with BD and healthy controls. 13 However in vascular BD patients they observed an increased EPC count, although not statistically significant. They were also unable to show any correlation between EPC High levels of endothelial progenitor cells and circulating endothelial cells in patients... Kutlay et al. found that the number of CECs was increased significantly in Behçet's vasculitis when compared to healthy controls.
They also showed that CEC levels were significantly higher in patients with active disease compared to those with inactive disease.
14 With regard to isolation of CECs, Kutlay et al. used the indirect cell separation technique, while others used flow cytometry. The mean plasma level of CECs (CD34+CD133+) in the present study was significantly higher in BD patients than in controls, but we found no correlation between CEC levels and disease activity ( Table 2 ). The CECs do not display disease activity in Behçet's disease.
ROC curve analysis was performed to demonstrate the utility of EPCs and CECs as disease activity markers in BD (Figure 3 ).
All the independent variables were found to be significant markers for BD. However, when compared to CRP and ESR as classical indicators of inflammation, EPCs and CECs were found to be weaker markers ( Figure 3A) . With regard to disease activity, similar findings were observed, except for CECs ( Figure 3B ). These results suggest that disease activity may result in elevated EPCs levels, which can be used as disease activity marker for BD, and the inflammatory endothelial cells released from lesions of ongoing/recent inflammation may result in increased CECs levels, which can be used as a marker of endothelial damage in BD. According to ROC curve analysis of CRP and ESR, these variables can be still useful inflammatory biomarkers for diagnosing and monitoring BD and disease activity ( Figure 3) . We have reported similar results in previous studies. [27] [28] [29] Mean plasma VEGF and MMP-9 were significantly higher in BD patients than in controls (Table 2 ). VEGF and MMP-9 levels were also higher in patients with active disease than in those with inactive disease. Pro-angiogenic factors such as VEGF can mobilize
EPCs and may enhance their recruitment to the site of endothelial injury. Previous studies have reported higher VEGF levels in many autoimmune and infectious inflammatory diseases. [30] [31] [32] There are limited numbers of studies that have measured VEGF levels in BD.
Most found that plasma VEGF levels were higher in BD patients than in controls, as in our study. [33] [34] [35] [36] [37] Only one study showed a significant association between VEGF level and disease activity in BD patients. 33 VEGF was presumed to be a marker of endothelial dysfunction. Our study also found significantly elevated VEGF levels in patients with active BD. We conclude that VEGF levels can be a helpful biomarker for disease activity in BD.
Matrix metalloproteinases are a family of calcium-or zinc-dependent endopeptidases that degrade the components of the extracellular matrix, playing a significant role in the release of EPCs from bone marrow. MMP-9 is a gelatinase, and it can degrade the subendothelial basement membrane by its elastinolytic activity. 38 It can thus play a crucial role in the pathogenesis of vasculitis especially characterized by aneurysm formation, as in BD. [39] [40] [41] Increased MMP-9 levels have been demonstrated in Kawasaki disease, temporal arteritis, and Takayasu's arteritis and were also found to correlated with disease activity score in TA. [40] [41] [42] Few studies have evaluated serum MMP-9 levels in BD. 39, [43] [44] [45] Most of them showed higher MMP-9 levels in BD patients than in controls, similar to our findings. MMP-9 showed a strong association with vascular BD, particularly with aneurysmal involvement, suggesting its pathogenetic role in vascular BD complicated by aneurysmal formation. 39 MMP-9 levels were also found to be increased in BD patients with visceral and ocular involvement. 44, 45 The above-mentioned findings suggest that systemic inflammation (increased CRP) and vascular endothelial damage (increased CECs) in BD, especially in the active period of the disease, result in increased VEGF release. The latter plays a vital role in inducing EPC levels in the bone marrow. Simultaneously, increased MMP-9 levels participate in the release of EPCs from the bone marrow into the peripheral circulation with the aim of reestablishing vascular integrity. The study has some limitations, such as the cross-sectional design. Patients were on medication, which has the potential to decrease EPC levels in the peripheral blood. One solution to offset these undesirable effects would be to increase the number of study participants. Our study had the largest patient sample of all studies published to date on this subject. Obtaining, analyzing and interpreting the data
CONCLUSION
